You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 9,994,627

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,994,627

Title:	Methods for purifying erythropoietin analogs having lower isoelectric point
Abstract:	The present invention relates to a method for purifying an erythropoietin analog having a low isoelectric point below 4 by adding an N-linked sugar chain with high purity. In accordance with the present invention, the erythropoietin analog having an isoelectric point below 4, which is an isoform having more sialic acid residues, can be effectively purified via three-step chromatographic processes in short time at lower cost.
Inventor(s):	Koh; Yeo-Wook (Yongin-Si, KR), Lee; Sang-Yong (Yongin-Si, KR), Kim; Cook-Hee (Yongin-Si, KR), Lee; Seung-Hui (Yongin-Si, KR), Kim; Ha-Na (Yongin-Si, KR), Kim; Su-Yon (Yongin-Si, KR), Seong; Jin-Hyun (Yongin-Si, KR), Cho; Yong-Hyun (Yongin-Si, KR)
Assignee:	CHONG KUN DANG PHARMACEUTICAL CORP. (Seoul, KR)
Application Number:	14/352,734
Patent Claims:	1. A method for purifying an erythropoietin (EPO) analog having an isoelectric point below 4, which analog is darbepoetin alfa, comprising obtaining a pretreated solution by removing animal cells from a culture solution of the animal cells, wherein the animal cells express the erythropoietin analog having an isoelectric point below 4; and, as the sole three chromatography steps of the method: (a) Obtaining a first fraction comprising the erythropoietin analog by subjecting the pretreated solution to first anion exchange chromatography; (b) Obtaining a second fraction comprising the erythropoietin analog by subjecting the first fraction to hydroxyapatite chromatography, whereby the second fraction is obtained as an unabsorbed fraction; and (c) Obtaining a third fraction comprising the erythropoietin analog by subjecting the second fraction to second anion exchange chromatography. 2. The method according to claim 1, wherein the animal cells expressing the erythropoietin analog comprise Chinese hamster ovary (CHO), VERO, HeLa, Wl38, baby hamster kidney (BHK), COS or Madin-Darby canine kidney (MDCK) cells. 3. The method of according to claim 1, wherein the obtaining of the pretreated solution is performed by (i) filtration through a depth filter and a membrane filter followed by ultrafiltration or (ii) centrifugation followed by ultrafiltration. 4. The method according to claim 1, wherein a buffer of pH below 4.0 is used as a washing buffer in the first anion exchange chromatography of the step (a). 5. The method according to claim 1, wherein a buffer of pH 2.0-4.0 is used as a washing buffer in the second anion exchange chromatography of the step (c). 6. The method according to claim 5, wherein the buffer contains glycine with a pH 2-3. 7. The method according to claim 6, wherein the buffer contains glycine with a pH 2.2-2.4. 8. The method according to claim 1, wherein the step (b) and the step (c) are performed as a single process.

Details for Patent 9,994,627

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen, Inc.	ARANESP	darbepoetin alpha	Injection	103951	09/17/2001	⤷ Try a Trial	2031-10-18
Amgen, Inc.	ARANESP	darbepoetin alpha	Injection	103951	07/19/2002	⤷ Try a Trial	2031-10-18
Amgen, Inc.	ARANESP	darbepoetin alpha	Injection	103951	12/17/2002	⤷ Try a Trial	2031-10-18
Amgen, Inc.	ARANESP	darbepoetin alpha	Injection	103951	12/12/2003	⤷ Try a Trial	2031-10-18
Amgen, Inc.	ARANESP	darbepoetin alpha	Injection	103951	06/29/2006	⤷ Try a Trial	2031-10-18
Amgen, Inc.	ARANESP	darbepoetin alpha	Injection	103951		⤷ Try a Trial	2031-10-18
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.